{"id":44528,"date":"2017-03-31T14:07:21","date_gmt":"2017-03-31T18:37:21","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=44528"},"modified":"2017-03-31T23:31:58","modified_gmt":"2017-04-01T04:01:58","slug":"biosimilares-en-latinoamerica","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/44528","title":{"rendered":"Biosimilares en Latinoamerica"},"content":{"rendered":"<p><strong>BIOSIMILARES<\/strong><\/p>\n<p>Am\u00e9rica Latina ve a los agentes biosimilares como un m\u00e9todo eficaz para reducir los gastos de atenci\u00f3n de la salud<\/p>\n<p>La verificaci\u00f3n de la similitud en la calidad, seguridad y eficacia de los biosimilares a el biol\u00f3gico innovador sigue siendo un desaf\u00edo clave para la pol\u00edtica de los fabricantes y las autoridades reguladoras de cada pa\u00eds<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-44530\" src=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/\/2017\/03\/biosimilares-1.jpg\" alt=\"\" width=\"859\" height=\"769\" srcset=\"https:\/\/piel-l.org\/blog\/wp-content\/uploads\/2017\/03\/biosimilares-1.jpg 859w, https:\/\/piel-l.org\/blog\/wp-content\/uploads\/2017\/03\/biosimilares-1-390x349.jpg 390w, https:\/\/piel-l.org\/blog\/wp-content\/uploads\/2017\/03\/biosimilares-1-768x688.jpg 768w\" sizes=\"auto, (max-width: 859px) 100vw, 859px\" \/><\/p>\n<p>Posterior a la aprobaci\u00f3n, la farmacovigilancia es cr\u00edtica para controlar la seguridad, incluyendo inmunogenicidad entre un agente biosimilar, producto de referencia y otros biosimilares<\/p>\n<p>La Farmacovigilancia para detectar diferencias en efecto adverso entre un biosimilar y el producto original pasa a ser el proceso mas importante despues de la comercializaci\u00f3n.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Am\u00e9rica Latina ve a los agentes biosimilares como un m\u00e9todo eficaz para reducir los gastos de atenci\u00f3n de la salud<\/p>\n","protected":false},"author":99,"featured_media":44529,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[276],"tags":[],"class_list":["post-44528","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-psoriasis-y-eccema"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/44528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/99"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=44528"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/44528\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media\/44529"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=44528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=44528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=44528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}